The trial realized both of those its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically important and exceptional advancements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH in comparison with placebo.onePl